Site icon Asrar Qureshi’s Blogs

Corruption in Pharmaceuticals – International Perspective 7 – Blog Post #501 by Asrar Qureshi

Dear Colleagues!  This is Pharma Veterans Blog Post #501. Pharma Veterans welcomes sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi onWordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here.

Continued from Previous…… This series is based on a report compiled by Jilian Clare Cohen1, Monique Mrazek2, and Loraine Hawkins3 for World Bank.

Six decision points were identified where corruption could infiltrate. The first was manufacturing, second was marketing authorization, third was selection, fourth is discussed below.

Decision Point Four: Procurement

[Quote] Procurement is the principal interface between the public system and drug suppliers, and its goal is to acquire the right quantity of drugs in the most cost-effective manner. Government functions in this decision point includes: inventory management, aggregate purchasing, public bidding contests, technical analysis of offers, the proper allocation of resources, payments, receipts of drugs purchased and quality control checks. Procurement is often poorly documented and processed, which makes it an easy target for corruption. [Unquote]

The procurement of publicly funded drug supplies is particularly at the risk of corruption because the volumes are high. To bring transparency in the process, the successive governments in Pakistan have been adding various procedural checks. Currently, it is quite an elaborate system which covers all stages of procurement process. Compared to many years ago, this is a more transparent system which encourages quality and economy and discourages malpractices. Despite criticism from various quarters, the overall process has certainly improved.

The report I am partaking from is largely focused on some African, Caribbean, and Latin American countries.

[Quote] The procurement of publicly funded drug supplies is particularly susceptible to corruption because drug volumes are usually large and the value of contracts is usually high even if unit costs are low, hence contracts can be very lucrative for suppliers. In the procurement process, domestic or international suppliers may pay public officials bribes to gain advantage at any of a number of steps in the tender process. Biased procurement methods can also be employed, such as the use of direct purchase when there is no emergency to justify it. This is due to several factors, including: the method to determine the volume of drugs needed is often subjective; there are difficulties in monitoring quality standards in drug provision; coordinating procurement and product registration processes in a timely way can be challenging if the pharmaceuticals licensing agency is inefficient and/or corrupt; suppliers use different prices for the same pharmaceutical products and can artificially inflate prices, and specifications for drug procurement can be tailored to suit the products of one supplier. All of these factors require strong oversight mechanisms within the public procurement process. If there is a lack of good governance in the procurement area possible adverse consequences include favouring of one supplier through the limiting of competition or the writing of biased specifications, purchasing of inappropriate products and the overpayment for products. [Unquote]

To improve the process of process of public procurement of drugs, the report recommends the following steps.

To be Continued……

Disclaimer. Most pictures in these blogs are taken from Google Images which does not show anyone’s copyright claim. However, if any such claim is presented, we shall remove the image with suitable regrets.

  1. Jilian Clare Cohen – Toronto, Canada
  2. Monique Mrazek – Latin America
  3. Loraine Hawkins – London

https://www.academia.edu/20118108/CORRUPTION_AND_PHARMACEUTICALS_STRENGTHENING_GOOD_GOVERNANCE_TO_IMPROVE_ACCESS?email_work_card=view-paper

Exit mobile version